Rituximab and cyclosporine therapy for accelerated phase Chediak-Higashi syndrome

Pediatric Blood and Cancer

Volumn 57, Issue 4, 2011, Pages 677-680

  Ogimi, Chikara ^a   Tanaka, Risa ^a   Arai, Takashi ^a   Kikuchi, Akira ^a   Hanada, Ryoji ^a   Oh ishi, Tsutomu ^a  

^a SAITAMA CHILDREN'S MEDICAL CENTER   (Japan)

Author keywords

Accelerated phase; Chediak Higashi syndrome; Cyclosporine; Epstein Barr virus (EBV); Hemophagocytic lymphohistiocytosis; Rituximab

Indexed keywords

BUSULFAN; CD19 ANTIGEN; CD8 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; ETOPOSIDE; METHYLPREDNISOLONE; RITUXIMAB; VIRUS DNA;

ARTICLE; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CASE REPORT; CELL FRACTIONATION; CHEDIAK HIGASHI SYNDROME; CHILD; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HUMAN; IN SITU HYBRIDIZATION; MALE; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REMISSION; T LYMPHOCYTE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CHEDIAK-HIGASHI SYNDROME; CYCLOSPORINE; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; HUMANS; IMMUNOLOGIC FACTORS; IN SITU HYBRIDIZATION; INFANT; MALE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79961181036     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23231     Document Type: Article

References (20)

1. Rubin CM, Burke BA, McKenna RW, et al. The accelerated phase of Chediak-Higashi syndrome. An expression of the virus-associated hemophagocytic syndrome? Cancer 1985;56:524-530.
2. Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Eur J Pediatr 2007;166:95-109.
3. Janka GE, Schneider EM. Modern management of children with haemophagocytic lymphohistiocytosis. Br J Haematol 2004;124:4-14.
4. Henter JI, Horne A, Arico M, et al. HLH-2004 diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48:124-131.
5. Conley ME, Henle W. Acyclovir in accelerated phase of Chediak-Higashi syndrome. Lancet 1987;1:212-213.
6. Aslan Y, Erduran E, Gedik Y, et al. The role of high dose methylprednisolone and splenectomy in the accelerated phase of Chediak-Higashi syndrome. Acta Haematol 1996;96:105-107.
7. Haddad E, Le Deist F, Blanche S, et al. Treatment of Chediak-Higashi syndrome by allogenic bone marrow transplantation: Report of 10 cases. Blood 1995;85:3328-3333.
8. Eapen M, DeLaat CA, Baker KS, et al. Hematopoietic cell transplantation for Chediak-Higashi syndrome. Bone Marrow Transplant 2007;39:411-415.
9. Sato S, Kawashima H, Oshiro H, et al. Virological and immunological characteristics of a 19-year-old Japanese female with fatal outcome with Epstein-Barr virus-associated hemophagocytic syndrome. J Clin Virol 2004;31:235-238.
10. Kasahara Y, Yachie A, Takei K, et al. Differential cellular targets of Epstein-Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Blood 2001;98:1882-1888.
11. Tosato G, Magrath I, Koski I, et al. Activation of suppressor T cells during Epstein-Barr-virus-induced infectious mononucleosis. N Engl J Med 1979;301:1133-1137.
12. Niedobitek G, Herbst H, Young LS, et al. Patterns of Epstein-Barr virus infection in non-neoplastic lymphoid tissue. Blood 1992;79:2520-2526.
13. Klein G, Klein E, Kashuba E. Interaction of Epstein-Barr virus (EBV) with human B-lymphocytes. Biochem Biophys Res Commun 2010;396:67-73.
14. Epstein AL, Henle W, Henle G, et al. Surface marker characteristics and Epstein-Barr virus studies of two established North American Burkitt's lymphoma cell lines. Proc Natl Acad Sci USA 1976;73:228-232.
15. Gupta S, Fricker FJ, Gonzalez-Peralta RP, et al. Post-transplant lymphoproliferative disorder in children: Recent outcomes and response to dual rituximab/low-dose chemotherapy combination. Pediatr Transplant 2010;14:896-902.
16. Gallego S, Llort A, Gros L, et al. Post-transplant lymphoproliferative disorders in children: The role of chemotherapy in the era of rituximab. Pediatr Transplant 2010;14:61-66.
17. Balamuth NJ, Nichols KE, Paessler M, et al. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol 2007;29:569-573.
18. Tsuda H, Shirono K. Successful treatment of virus-associated haemophagocytic syndrome in adults by cyclosporin A supported by granulocyte colony-stimulating factor. Br J Haematol 1996;93:572-575.
19. Watson HG, Goulden NJ, Manson LM, et al. Virus-associated haemophagocytic syndrome: Further evidence for a T-cell mediated disorder. Br J Haematol 1994;86:213-215.
20. Imashuku S, Kuriyama K, Teramura T, et al. Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol 2001;19:2665-2673.